Management of Autoimmune Hemolytic Anemia in Patients with Chronic Kidney Disease on Dialysis

Diagnosis and Initial Evaluation

AIHA should be suspected in CKD patients on dialysis when hemoglobin levels fall below expected ranges despite adequate erythropoietin therapy, with diagnostic workup initiated when hemoglobin falls below 11 g/dL in pre-menopausal females and pre-pubertal patients, or below 12 g/dL in adult males and post-menopausal females 1, 2
Blood samples for anemia evaluation should be obtained pre-dialysis, using automated cell counters for standardized results 2

The National Kidney Foundation recommends ensuring adequate iron stores are maintained with TSAT ≥20% and serum ferritin ≥100 ng/mL to support erythropoiesis 3

The American Journal of Kidney Diseases suggests maintaining hemoglobin targets generally in the range of 11.0-12.0 g/dL for CKD patients on dialysis receiving ESA therapy 4
Avoid targeting hemoglobin levels above 13.0 g/dL due to increased risk of life-threatening cardiovascular events 4, 5
Ensure adequate iron supplementation, preferably intravenous iron in hemodialysis patients, to maintain TSAT ≥20% and serum ferritin ≥100 ng/mL 3, 6
Monitor iron status by measuring TSAT and serum ferritin at least every 3 months 6

Evaluate for potential causes of inadequate response to erythropoietin therapy, including infection/inflammation, chronic blood loss, osteitis fibrosa, and aluminum toxicity 8
Consider the impact of angiotensin-converting enzyme inhibitors (ACE-I), which may potentially inhibit the action of erythropoietin in some patients 7
Monitor for and address nutritional deficiencies (folate, vitamin B12) that may exacerbate anemia 8

Adjust erythropoietin doses based on response and hemoglobin targets 4, 5
For Epoetin-resistant patients with AIHA, higher doses may be required, with careful monitoring for potential adverse effects 7, 8